CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bausch Health Companies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bausch Health Companies Inc
2150 Saint-Elzear Blvd W
Phone: (514) 744-6792p:514 744-6792 LAVAL, QC  H7L 4A8  Canada Ticker: BHCBHC
Business Summary
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
3841 Surgical and medical instruments and apparatus
3842 Orthopedic, prosthetic, and surgical appliances and supplies
3843 Dental equipment and supplies
3851 Ophthalmic goods

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board John A.Paulson 67 6/23/2022 6/14/2017
Chief Executive Officer, Director Thomas J.Appio 61 5/10/2022 4/1/2016
Chief Financial Officer, Executive Vice President Tom G.Vadaketh 60 5/10/2022 5/10/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
12279967 Canada Ltd.
12283778 Canada Ltd.
1261229 B.C. Ltd.
141 additional Business Names available in full report.

General Information
Number of Employees: 19,900 (As of 12/31/2022)
Outstanding Shares: 364,334,264 (As of 7/28/2023)
Shareholders: 1,800
Stock Exchange: NYSE
Federal Tax Id: 980448205
Fax Number: (514) 744-6792
Email Address: ir@biovail.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023